leisure time -WSS

leisure time

author：leisure time 2025-09-27 16:22:56 - browse：881

A photo of Robert Blum speaking at the STAT Summit West on May 16, 2024 — Cytokinetics CEO Robert Blum spoke Thursday at a talk during STAT’s Breakthrough Summit West in San Francisco. Sarah Gonzalez for STAT

As Cytokinetics faces pressure to sell itself to a large pharma company following positive late-stage results of its heart drug, CEO Robert Blum maintains that the biotech can launch the treatment — what would be its first approved medication — on its own.

Cytokinetics reported top-line results of its drug, aficamten, in obstructive hypertrophic cardiomyopathy, or oHCM, last December, sending its shares up on speculation the company would get acquired. Full Phase 3 results released this week further suggest the drug could be used more flexibly than a similar treatment sold by Bristol Myers Squibb, but investors have questioned whether the biotech has the resources and salesforce to compete with a large pharma company.

Blum, speaking Thursday at a talk during STAT’s Breakthrough Summit West, said that if prospective buyers approach the company, he will talk to them, but “at the same time, we’re pushing forward, as we always have, with the original intention to build a commercial business. And that’s not something new. That’s not something that’s a result of a failed M&A dialogue.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Meta's Zuckerberg and Chan on track to put $50 billion into science

WSS

Diversifying clinical trials isn't enough to close racial gaps: study

STAT Readout Newsletter: Today in biotech, life science news

Massive project maps cells in human brain in unprecedented detail

Akero's treatment for NASH falls short in cirrhosis study

Readout LOUD podcast: Merger Mondays, Ozempic panic

Hospitals warn Medicare's drug payment fix is ‘unlawful’

hotspot

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

Apple is now the first public company to be valued at $3 trillion

STAT Wunderkinds: Ruey Hu's digital tools for parsing research

Medicare proposal to cover medical devices draws a mixed reaction

Humana CEO Bruce Broussard to step down in 2024

Hepatitis C has a cure — but many Americans still lack access to it

Chimpanzees, like humans and whales, get menopause: Study

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

STAT Wunderkinds: Ruey Hu's digital tools for parsing research

Medical records are filled with copy

Chimpanzees, like humans and whales, get menopause: Study

entertainment

STAT Readout: Today's biotech news includes Sana and Amylyx

What the Wegovy shortage looks like for doctors — and for patients

Eli Lilly to pay $200M for Beam’s stake in gene

Life sciences deals on track to hit lowest point since 2017

European regulators consider appeal over Amylyx ALS drug

First Opinion Podcast: How to protect health care in times of war

Wikipedia

entertainment

leisure time

focus